Loading news...
Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expectations for Federal Reserve rate cuts later this year, as a weaker-than-expected start to the earnings season kept investors cautious.
Moderna is undergoing a strategic shift, prioritizing infectious disease, oncology, and rare diseases to achieve cash break-even by 2028. 2026 is pivotal, with multiple oncology catalysts—especially Intismeran/Keytruda Phase II and III readouts—potentially driving future revenue and valuation. MRNA maintains a speculative 'Buy' rating for high-risk, long-term investors, supported by disciplined cost reductions and a maturing pipeline.
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously communicated guidance of $1.6 to $2 billion. The company also raised its 2025 GAAP operating expense outlook by $200 million to a range of $5 to $5.2 billion and projects a year-end cash balance of approximately $8.1 billion, including a $0.6 billion drawdown from a recently announced $1.5 billion term loan facility.
Moderna also reiterates its expectations for revenue growth of up to 10% in 2026.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously...
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below revenue levels achieved during the COVID-19 pandemic.
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call Improves 2025 expected GAAP operating expenses by $200 million since 3Q25 Earnings Call Increases 2025 projected year-end cash balance to approximately $8.1 billion (unaudited) Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026 Anticipates potential first approvals of flu and flu/COVID combination products in 2026 Expects pivotal trial data readouts in oncology, rare disease and infectious disease in 2026 CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products and delivering pivotal readouts across oncology, rare disease and infectious disease portfolios.
In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% in just three trading days, and the technicals suggest the move may not be a fluke.
Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.
Pre-Market Stock Futures: The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit another record high, closing over $49,000 for the first time at $49,484, up a solid 1.04%. The S&P 500 also posted a record high, closing at 6,947, up 0.66%. The... Here Are Wednesday's Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonald's, Moderna, and More.
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
These stocks, ranging from technology to healthcare, could add diversification to your portfolio. Four have proven their earnings strength; the fifth makes a solid recovery story bet.
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sold as a victory for “individual choice.
Tamboran Resources Corporation (ASX:TBN, NYSE:TBN, OTC:TBNRL) has moved a step closer to consolidating full ownership of Falcon Oil & Gas Australia Ltd...
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has delivered record quarterly revenue of $3.2 million for the quarter ended December 31, 2025, supported by ongoing...
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) on Monday reiterated its 2025 revenue guidance of $1.6 billion to $2.0 billion and outlined its pipeline milestones for 2026-28, with the company continuing to focus on Covid-19 as its near-term revenue driver. In its annual letter, Moderna highlighted that its Covid vaccines remain central to 2026, with the mNEXSPIKE vaccine representing roughly 24% of all US retail Covid vaccinations in 2025 and nearly one-third of vaccinations among adults aged 65 and older.